David Natan's most recent trade in Cyclacel Pharmaceuticals Inc was a trade of 700,000 Non-Qualified Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 26, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cyclacel Pharmaceuticals Inc | David Natan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 700,000 | 700,000 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cyclacel Pharmaceuticals Inc | David Natan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 100,000 | 100,000 (0%) | 0% | - | Common Stock | |
| Opgen Inc | David Natan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Apr 2024 | 100,000 | 100,000 (1%) | 1% | - | Common Stock | |
| Titan Pharmaceuticals, Inc... | David Natan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2023 | 100,000 | 100,000 | - | - | Option to Purchase Common Stock | |
| Titan Pharmaceuticals, Inc... | David Natan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2023 | 50,000 | 50,000 (0%) | 0% | 0 | Common Stock | |
| Titan Pharmaceuticals, Inc... | David Natan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2023 | 25,000 | 25,000 | - | - | Option to Purchase Common Stock |